Experienced in D-Plus Hemolytic Uremic Syndrome

Angel A. Calatayud-Perez

Mexico City, DIF, MX 
Experienced in D-Plus Hemolytic Uremic Syndrome
Mexico City, DIF, MX 
OverviewLocationsClinical Research

Overview

Angel Calatayud-Perez practices in Mexico City, Mexico. Calatayud-Perez is rated as an Experienced expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. Their top areas of expertise are Familial Hypofibrinogenemia, Congenital Afibrinogenemia, Thrombocytopenia, and COVID-19.

Their clinical research consists of co-authoring 25 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of D-Plus Hemolytic Uremic Syndrome.

Locations

Mexico City, DIF, Mexico
Other Locations
Mexico, MEX 06720, Mexico
Hospital General De México Dr. Eduardo Liceaga, La Ciudad, DUR, Mexico
Hospital de Especialidades del Niño y la Mujer Dr. Felipe Núñez Lara
Santiago De Queretaro, QUE, Mexico
Valle De Mexico, MEX, Mexico

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial
Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial
Enrollment Status: Completed
Publish Date: December 21, 2020
Intervention Type: Biological, Other
Study Phase: Phase 2

25 Total Publications

Neutrophil-Mediated Inflammatory Plasminogen Degradation, Rather Than High Plasminogen-Activator Inhibitor-1, May Underly Failures and Inefficiencies of Intrapleural Fibrinolysis.
Neutrophil-Mediated Inflammatory Plasminogen Degradation, Rather Than High Plasminogen-Activator Inhibitor-1, May Underly Failures and Inefficiencies of Intrapleural Fibrinolysis.
Journal: Chest
Published: December 28, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Calatayud-Perez's expertise for a condition
ConditionClose
        View All 17 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile